ArticleFrontiers in immunology2024

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.

Olalekan O Oluwole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.